Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03651271
Title Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Parker Institute for Cancer Immunotherapy
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.